Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment, and when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also depend on the severity of initial depression scores. The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials. METHODS AND FINDINGS: We obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants for which full datasets were available. We then used meta-analytic techniques to assess linear and quadratic effects of initial severity on improvement scores for drug and placebo groups and on drug-placebo difference scores. Drug-placebo differences increased as a function of initial severity, rising from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression, reaching conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category. Meta-regression analyses indicated that the relation of baseline severity and improvement was curvilinear in drug groups and showed a strong, negative linear component in placebo groups. CONCLUSIONS: Drug-placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients. The relationship between initial severity and antidepressant efficacy is attributable to decreased responsiveness to placebo among very severely depressed patients, rather than to increased responsiveness to medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Individual-level meta-analyses have found a direct relationship between the magnitude of depressive symptoms and the effectiveness of antidepressants.8–10”
From Comparative effectiveness of exercise, antidepressants and their combination in treating non-severe depression: a systematic review and network meta-analysis of randomised controlled trials (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An understanding of users’ own experiences of antidepressant use is increasingly important in the context of growing doubts about the effectiveness of antidepressant treatment [5, 26], concerns about side effects [27] and withdrawal effects [28].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [5]
In the citing paper
“In this study, 84 % of participants in this study answered in the affirmative to a question about whether they felt antidepressants had reduced their depression, a number well above that suggested by efficacy studies”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [5]
In the citing paper
“Other studies have found support for increasing benefit with increasing severity of depression,21 but the effects size even for patients with the most severe depression was still minimal.21”
From Should antidepressants be used for major depressive disorder? (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“Both Q [15] and I2 [ 16 ] indices were used to assess”
MethodStatistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
Meta-analysis in social research
(1982) · Evaluation and Program Planning · doi:10.1016/0149-7189(82)90011-8 · Cited by 3,853 · cited 1×
“Finally, to show directly the amount of improvement for each study’s drug group against its placebo group, we calculated the difference between the change for the drug group minus the change for the placebo group, leaving the difference in raw units and deriving its analytic weight from its standard error [11,12,20].”
MethodImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“s were known for 28 groups, could be calculated from other inferential statistics in nine comparisons (18 groups), and were imputed in 12 comparisons (24 groups) (47.38%) [”
InfluentialPublication bias in meta-analysis its causes and consequences
Thornton, A. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00161-4 · Cited by 1,291 · cited 1×
“Examination of publication bias often relies on inspections of effect sizes in relation to sample size (or inverse variance) [22].”
BackgroundThe power of statistical tests for moderators in meta-analysis
Hedges, L. V., & Pigott, T. D. (2004) · Psychological Methods · doi:10.1037/1082-989x.9.4.426 · Cited by 672 · cited 1×
“A last, mixedeffects analysis for the amount of change used a randomeffects constant along with fixed-effects moderator dimensions; these models provide more conservative assessments of moderation [19].”
MethodMelander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635 · cited 2×
“In the case of antidepressant medication, this limitation has been found to result in considerable reporting bias characterized by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies [5].”
BackgroundPlacebo Theory, Research , and Mechanisms
WHITE, L. E., Tursky, B., & SCHWARTZ, G. E. R. (1985) · Guilford Press eBooks · Cited by 485
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456 · cited 2×
“Similar to prior reports [3,4], this analysis of U.”
BackgroundResultKirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.523a · Cited by 422 · cited 1×
“]. Analyses of datasets including unpublished as well as published clinical trials reveal smaller effects that fall well below recommended criteria for clinical effectiveness. Specifically, a meta-analysis of clinical trial data submitted to the US Food and Drug Administration (FDA) revealed a mean drug–placebo differ…”
BackgroundInfluentialSelf-citationSchmidt, F. L., Le, H., & Ilies, R. (2003) · Psychological Methods · doi:10.1037/1082-989x.8.2.206 · Cited by 362
Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia
Benedetti, F., Arduino, C., & Amanzio, M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03639.1999 · Cited by 350 · cited 1×
“In contrast, the effect of placebo on pain is estimated to be about 50% of the response to pain medication [24–26].”
BackgroundHansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 255 · cited 2×
“A prior meta-analysis of published data only reported a very small significant difference between the antidepressant effect of fluoxetine and venlafaxine, but did not assess the effect of baseline severity as a moderator [23].”
BackgroundStark, P., & Hardison, C. D. (1985) · PubMed · Cited by 239
Estimation of Effect Size From a Series of Experiments Involving Paired Comparisons
Gibbons, R. D., Hedeker, D. R., & Davis, J. M. (1993) · Journal of Educational Statistics · doi:10.3102/10769986018003271 · Cited by 230 · cited 1×
“We conducted two types of data analysis, one in which each group’s change was represented as a standardized mean difference (d), which divides change by the standard deviation of the change score (SDc) [10], and another using each study’s drug and placebo groups’ arithmetic mean (weighted for the inverse of the varian…”
MethodInvestigating underlying risk as a source of heterogeneity in meta-analysis
Thompson, S. G., Smith, T. C., & Sharp, S. J. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971215)16:23<2741::aid-sim703>3.0.co;2-0 · Cited by 226 · cited 1×
“Analyses examining linear and quadratic functions for baseline levels of severity used zero-centered forms of this variable [18].”
BackgroundEffectiveness of venlafaxine in patients hospitalized for major depression and melancholia.
Guelfi, J., White, C. M., Hackett, D., Guichoux, J. Y., & Magni, G. (1995) · PubMed · Cited by 170
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159 · cited 1×
“Venlafaxine (Wyeth Pharmaceuticals) 203 [30] 25.6 11.2 1.37 [1.19, 1.55] 231 25.3 6.7 0.82 [0.58, 1.06] 92 301 [31,32] 25.4 13.9 1.77 [1.36, 2.17] 64 24.6 9.45 1.20 [0.91, 1.50] 78 302 [ 33 ] 25 11.9 1.16 [0.84, 1.49] 65 24.4 8.88 0.87 [0.60, 1.14] 75 303 23.6 10.1 1.27 [0.94, 1.59] 69 24.6 9.89 1.24 [0.94, 1.54] 79 3…”
InfluentialRudolph, R. L., Fabre, L. F., Feighner, J. P., Rickels, K., Entsuah, R., & Derivan, A. T. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0305 · Cited by 132 · cited 1×
“Venlafaxine (Wyeth Pharmaceuticals) 203 [30] 25.”
Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
Schweizer, E. E., Feighner, J. P., Mandos, L. A., & Rickels, K. (1994) · PubMed · Cited by 128
Nefazodone and Imipramine in Major Depression: A Placebo-Controlled Trial
Rickels, K., Schweizer, E., Clary, C., Fox, I., & Weise, C. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.6.802 · Cited by 123 · cited 1×
“CN104–005 [40] 24.”
A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
Fontaine, R., Ontiveros, A., Elie, R., Kensler, T. T., Roberts, D. L., Kaplita, S., Ecker, J., & Faludi, G. (1994) · PubMed · Cited by 117
Meta-Analysis of Raw Mean Differences.
Bond, C. F., Wiitala, W. L., & Richard, F. D. (2003) · Psychological Methods · doi:10.1037/1082-989x.8.4.406 · Cited by 112 · cited 1×
“s, the standardized mean difference was used in moderator analyses in order to attain better-fitting models [”
MethodOptimal dose regimen for paroxetine.
Dünner, D. L., & Dunbar, G. C. (1992) · PubMed · Cited by 111
Thiessen‐Philbrook, H., Barrowman, N. J., & Garg, A. X. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.018 · Cited by 99 · cited 1×
“In total, SDcs were known for 28 groups, could be calculated from other inferential statistics in nine comparisons (18 groups), and were imputed in 12 comparisons (24 groups) (47.38%) [13, 14 ].”
BackgroundInfluentialEfficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
MENDELS, J., Johnston, R. B., Mattes, J. A., & Riesenberg, R. A. (1993) · PubMed · Cited by 80
A placebo-controlled trial of paroxetine in the treatment of major depression.
Smith, W. T., & Glaudin, V. (1992) · PubMed · Cited by 80
Mendels, J., Reimherr, F. W., Marcus, R. N., Roberts, D. L., Francis, R. J., & Anton, S. F. (1995) · PubMed · Cited by 75
Paroxetine in the treatment of depression: a comparison with imipramine and placebo
Feighner, J. P., & Boyer, W. F. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07190.x · Cited by 68
Paroxetine in major depression: a double-blind trial with imipramine and placebo.
Schatzberg, A. F., & Rothschild, A. J. (1992) · PubMed · Cited by 64
A placebo‐controlled, double‐blind, clinical trial of paroxetine in depressed outpatients
Rickels, K., Amsterdam, J., Clary, C., Fox, I., Schweizer, E., & Weise, C. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07188.x · Cited by 59 · cited 1×
“Paroxetine (GlaxoSmithKline) 01–001 28 13.5 1.67 [0.99, 2.34] 24 27.4 10.5 1.30 [0.71, 1.88] 24 02–001 [ 41 ,42] 26.6 12.3 1.28 [0.89, 1.66] 51 25.9 6.8 0.70 [0.39, 1.01] 53 02–002 [43,44] 25 10.9 1.23 [0.78, 1.69] 36 24.9 5.8 0.66 [0.27, 1.04] 34 02–003 [45] 28.6 9.7 0.93 [0.50, 1.35] 33 28.9 7.2 0.69 [0.29, 1.08] 33…”
InfluentialPattern analysis shows beneficial effect of fluoxetine treatment in mild depression.
Dunlop, S. R., Dornseif, B. E., Wernicke, J., & Potvin, J. H. (1990) · PubMed · Cited by 59
Jensen, S. B., Schaumburg, E., Leroy, B., Larsen, B. Ø., & Thorup, M. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb01313.x · Cited by 56
Dose-Response Relationship With Venlafaxine
KELSEY, J. E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00005 · Cited by 48 · cited 1×
“Venlafaxine (Wyeth Pharmaceuticals) 203 [30] 25.6 11.2 1.37 [1.19, 1.55] 231 25.3 6.7 0.82 [0.58, 1.06] 92 301 [31,32] 25.4 13.9 1.77 [1.36, 2.17] 64 24.6 9.45 1.20 [0.91, 1.50] 78 302 [33] 25 11.9 1.16 [0.84, 1.49] 65 24.4 8.88 0.87 [0.60, 1.14] 75 303 23.6 10.1 1.27 [0.94, 1.59] 69 24.6 9.89 1.24 [0.94, 1.54] 79 313…”
InfluentialParoxetine in the treatment of depression: a comparison with imipramine and placebo.
Feighner, J. P., & Boyer, W. F. (1992) · PubMed · Cited by 44
Peselow, E. D., Filippi, A.-M., Goodnick, P. J., Barouche, F., & Rr, F. (1989) · PubMed · Cited by 39
A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
Fabre, L. F. (1992) · PubMed · Cited by 39
A placebo- and imipramine-controlled study of paroxetine.
Cohn, J. B., Crowder, J. E., Wilcox, C. S., & Ryan, P. J. (1990) · PubMed · Cited by 39
A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
Kiev, A. (1992) · PubMed · Cited by 38
A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
Shrivastava, R. K., Shrivastava, S. H., Overweg, N. I. A., & Blumhardt, C. L. (1992) · PubMed · Cited by 34
Claghorn, J. L. (1992) · PubMed · Cited by 32
Placebo-controlled dose-ranging trial designs in phase II development of nefazodone.
D’Amico, M. F., Roberts, D. L., Robinson, D. S., SCHWIDERSKI, U. E., & Copp, J. (1990) · PubMed · Cited by 31
A Double-Blind Comparison of Paroxetine and Placebo in the Treatment of Depressed Outpatients
Claghorn, J. L. (1992) · International Clinical Psychopharmacology · doi:10.1097/00004850-199206004-00006 · Cited by 24 · cited 1×
“Paroxetine (GlaxoSmithKline) 01–001 28 13.5 1.67 [0.99, 2.34] 24 27.4 10.5 1.30 [0.71, 1.88] 24 02–001 [41,42] 26.6 12.3 1.28 [0.89, 1.66] 51 25.9 6.8 0.70 [0.39, 1.01] 53 02–002 [ 43 ,44] 25 10.9 1.23 [0.78, 1.69] 36 24.9 5.8 0.66 [0.27, 1.04] 34 02–003 [45] 28.6 9.7 0.93 [0.50, 1.35] 33 28.9 7.2 0.69 [0.29, 1.08] 33…”
InfluentialThe efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
Rickels, K., Amsterdam, J. D., Clary, C. M., Fox, I., Schweizer, E. E., & Weise, C. (1992) · PubMed · Cited by 24
Miller, S. M., Naylor, G. J., Murtagh, M., & Winslow, G. S. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07197.x · Cited by 17 · cited 1×
“... 1.06] 38 03–002 [49,50] 24.9 8 1.14 [0.72, 1.55] 40 25.6 6.2 0.88 [0.50, 1.26] 40 03–003 25.7 9.9 1.18 [0.76, 1.59] 41 27 10 1.19 [0.78, 1.60] 42 03–004 [51] 27.6 10.4 1.33 [0.86, 1.79] 37 27 6.7 0.86 [0.46, 1.25] 37 03–005 [52] 26.1 10 0.99 [0.60, 1.39] 40 26.8 4.1 0.41 [0.08, 0.73] 42 03–006 [53] 29.7 9.1 1.11 […”
InfluentialAngst, J. (1993) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470080605 · Cited by 16 · cited 2×
“Similar to prior reports [ 3 ,4], this analysis of U.S.”
BackgroundResultClinical Evaluation of Venlafaxine
BALLENGER, J. C. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00007 · Cited by 14 · cited 4×
“Venlafaxine (Wyeth Pharmaceuticals) 203 [30] 25.6 11.2 1.37 [1.19, 1.55] 231 25.3 6.7 0.82 [0.58, 1.06] 92 301 [31,32] 25.4 13.9 1.77 [1.36, 2.17] 64 24.6 9.45 1.20 [0.91, 1.50] 78 302 [33] 25 11.9 1.16 [0.84, 1.49] 65 24.4 8.88 0.87 [0.60, 1.14] 75 303 23.6 10.1 1.27 [0.94, 1.59] 69 24.6 9.89 1.24 [0.94, 1.54] 79 313…”
BackgroundMethodInfluentialI2 Is Subject to the Same Statistical Power Problems as Cochran's Q
Huedo-Medina, T. B., & Johnson, B. T. (2007) · OpenCommons - UConn (University of Connecticut) · Cited by 4
Self-citation
Research works printed but not linked: 3
- Lipsey MW Wilson DB 2001 Practical meta-analysis. Applied social research methods Volume 49. Thousand Oaks (California) Sage Publications 247
- Evans FJ 1974 The placebo response in pain reduction Adv Neurol 4 289 296
- Fabre LF Crimson L 1985 Efficacy of fluoxetine in outpatients with major depression Curr Ther Res Clin Exp 37 115 123
Cited by
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
“Therefore, we present analyses only on data for medications for which complete clinical trials’ change was reported” (147).”
MethodLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Italian Journal of Public Health · doi:10.2427/5768 · Cited by 3,374
Metadata
- Authors
- Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T.
- Affiliations
- University of Hull (GB)
- University of Wyoming (US)
- University of Connecticut (US)
- University of Windsor (CA)
- Institute for Safe Medication Practices (US)
- Corresponding author
- Kirsch, Irving
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-02-26
- Volume
- 5
- Issue
- 2
- Pages
- e45
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2253608
- OpenAlex
- W2153403353
- Cited by
- 2,442
- References
- 49
- Citations by year
- 2026: 47 · 2025: 53 · 2024: 63 · 2023: 65 · 2022: 90 · 2021: 81 · 2020: 132 · 2019: 100 · 2018: 159 · 2017: 154 · 2016: 142 · 2015: 130 · 2014: 156 · 2013: 191 · 2012: 179
- FWCI
- 24.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, antidepressant efficacy, placebo response, severe depression, clinical significance
- MeSH terms
- Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Humans, Severity of Illness Index, United States, United States Food and Drug Administration, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.